logo
Share SHARE
FONT-SIZE Plus   Neg

NovaBay Pharma, Virbac Animal Health Ink Option Deal For Aganocide Compounds

NovaBay Pharmaceuticals Inc. (NBY) said it has reached a feasibility and option agreement with Virbac Animal Health for the development and potential commercialization of Aganocides for a number of veterinary use. As per the deal, NovaBay would receive an upfront payment plus additional support for research and development.

Virbac would conduct veterinary studies using NovaBay's Aganocide compounds in order to assess feasibility for treating several veterinary indications, and it would have the option to license exclusive worldwide rights to market Aganocides for one or more of these indications. If exercised, NovaBay may receive additional payments, including an exercise fee as well as development and pre-commercial milestones for a line of veterinary products. Also, NovaBay would receive royalties on sales of any commercialized Aganocide products to arise from this agreement.

NovaBay is developing its first-in-class, non-antibiotic, anti-infective Aganocide compounds for the topical treatment and prevention of a wide variety of bacterial, viral and fungal infections.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
President Donald Trump has continued his assault on one of his favorite targets on Wednesday, lashing out at major media outlets in a series of posts on Twitter. Trump singled out the New York Times and the Washington Post in his tweets, describing the newspapers as "fake news." Christoph, born on-board a Spirit flight destined to Dallas from Fort Lauderdale airport, can celebrate all his forthcoming birthdays in life with a free travel on Spirit airline. Blue Apron Holdings Inc. has cut the expected price range for its initial public offering amid worries about the potential impact on the food retail sector of Amazon.com Inc.'s recent deal to buy grocery chain Whole Foods Market Inc. for $13.7 billion.
comments powered by Disqus
Follow RTT